Germany’s benefit assessment system for new drugs needs to be more flexible in terms of the evidence that it requires, say R&D-based pharmaceutical industry associations. The comments come in response to findings by the German health technology assessment (HTA) body, IQWiG, that more than half the new drugs entering the country’s health care system offer no additional benefit compared to existing therapies.
New post-launch evidence generation tools could help prove a new drug’s additional benefit, said Alexander Natz, secretary general of the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?